Anda! Menudos son! Veo q tienes enchufe! Jajaja Mil gracias PD el insider metió $10 M el otro día x lo q no me fije en el low float Otras q les pedí en el pasado como BCYC tienen tb escaso y no tuvieron problema en ponerlo Xa mi q andan de vacaciones o algo además han sido más lentos que nunca
CASH: -As of March 31, 2020, we had cash, cash equivalents and marketable securities of $130.4 million. We believe that our existing cash, cash will enable us to fund expenses and capital expenditureinto the first quarter of 2022.
ÚLTIMO OFFERING: - We are offering 7,500,000 shares of our common stock, par value $0.001 per share. Our common stock is listed on the Nasdaq Global Market under the symbol “MGTA.” On June 23, 2020, the last reported sale price of our common stock was $10.30 per share. / El precio del offering fué pero: at a price to the public of $8.00 per share.
COMPETIDORES: - Competitors in our cell therapy programs include: Gamida Cell Ltd., ExCellThera Inc., Angiocrine Bioscience, Inc. and Intellia Therapeutics, Inc. In particular, Intellia Therapeutics, Inc. has exclusively licensed from Novartis the aryl hydrocarbon receptor antagonist that we use to manufacture MGTA-456 for expansion of gene-modified HSCs only, and it is likely that the programs developed under this license would compete directly with our E478 program.
-We also face competition in our conditioning programs from Actinium Pharmaceuticals, Inc., Jasper Therapeutics, Inc., and Molecular Templates, Inc., and in our post-transplant complications program from Bellicum Pharmaceuticals, Inc., Abbvie Inc. and Incyte Corporation.
-Additionally, BioLineRx Ltd. is a competitor in our mobilization program.
In addition, we anticipate competing with the largest pharmaceutical companies in the world, such as Novartis, which is currently conducting research relating to expansion of HSCs that have been modified using CRISPR/Cas9 technology to express therapeutic proteins and delivered to patients for the treatment of potential treatment of blood disorders or primary immune deficiencies, which has greater financial and human resources than we currently have.
EL INSIDER: Parece que compró para el fund ATLAS
Otras compras del Booth Bruce (ATLAS) -> AVRO
#123269
Re: Farmas USA
Una trabajo excelente. Enhorabuena.
#123270
Re: Farmas USA
NVAX deunido esta en modo monsutro no? market cap de 224M a 7bn, lo que hay que ver, si casi está a precios pre catastrofe ( yo entonces ni operaba, pero de seguir un poco la historia) me sabe mal pues tanto NVAX como AMRN efectivamente tenian algo ahí de razón de ser y potencial, pero ha tardado 4-5 años en hacer la mega subida...pero algo había si.. se hicieron esperar,
El corto de fer hoy ocmienza mal, no sé que cantidades son 250 en cfd ni idea, espero que no sea mucho el daño, veo que está en market cap muy alto y uqe le tocaria short, pero ir contra esa tendencia uau, la flota es pequeña ademas, me constan 60m, más sujeta a volatilidades
Dr. Richardson explains that several medications, both anti-inflammatories and antithrombotics are being used to control the worst consequences of COVID-19. In addition to dexamethasone, both selinexor and ibrutinib are showing promise in treating COVID-19 while a vaccine is still being developed.
